About: Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials
Creator	Dabbous, Monique Han, Ru Liang, Shuyao Qiu, Tingting Toumi, Mondher Wang, Yitong Nowotarska, Anna
Source	MedRxiv
abstract	Purpose: This study aims to critically assess the published studies of Chloroquine (CQ) and hydroxychloroquine (HCQ) for the treatment of COVID-19 and provide recommendations for future clinical trials for the COVID-19 pandemic. Method: A rapid systematic review was conducted by searching the PubMed, Embase, and China National Knowledge Infrastructure databases on April 13, 2020. Three clinical trial registry platforms, including ClinicalTrials.gov, the EU Clinical Trials Register, and the Chinese Clinical Trial Register were also complementarily searched. Results: A total of 10 clinical studies were identified, including 3 randomized controlled trials (RCTs), 1 comparative nonrandomized trial, 5 single-arm trials, and 1 interim analysis. The heterogeneity among studies of the baseline disease severity and reported endpoints made a pooled analysis impossible. CQ and HCQ (with or without azithromycin) showed significant therapeutic benefit in terms of virologic clearance rate, improvement in symptoms and imaging findings, time to clinical recovery, and length of hospital stay in 1 RCT, 4 single-arm trials, and the interim analysis, whereas no treatment benefit of CQ or HCQ was observed in the remaining 4 studies. Limitations of the included studies ranged from small sample size, to insufficient information concerning baseline patient characteristics, to potential for selection bias without detailing the rationale for exclusion, and presence of confounding factors. Conclusion: Based on the studies evaluated, there still lacked solid evidence supporting the efficacy and safety of HCQ and CQ as a treatment for COVID-19 with or without azithromycin. This emphasized the importance of robust RCTs investing HCQ/CQ to address the evidence uncertainties. Keywords: COVID-19, Systematic review, Clinical trial, Chloroquine, Hydroxychloroquine
has issue date	2020-06-01(xsd:dateTime)
bibo:doi	10.1101/2020.06.01.20118901
has license	medrxiv
sha1sum (hex)	e66b1a8301056261858b135ad04a00ef15ac1b4e
schema:url	https://doi.org/10.1101/2020.06.01.20118901
resource representing a document's title	Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials
resource representing a document's body	covid:e66b1a8301056261858b135ad04a00ef15ac1b4e#body_text
is schema:about of	covid:arg/e66b1a8301056261858b135ad04a00ef15ac1b4e named entity 'provide' named entity 'clinical trials' named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'systematic review' named entity 'COVID-19 pandemic' named entity 'clinical trials' named entity 'Title page' named entity 'clinical trials' named entity 'COVID-19' named entity 'assess' named entity 'randomly assigned' named entity 'risk factors' named entity 'HCQ' named entity 'HCQ' named entity 'chloroquine' named entity 'HCQ' named entity 'follow-up' named entity 'HCQ' named entity 'clinical trials' named entity 'medRxiv' named entity 'antiviral therapies' named entity 'pneumonia' named entity 'viral shedding' named entity 'Pneumonia' named entity 'HCQ' named entity 'cytokine storm' named entity 'retinopathy' named entity 'CT scan' named entity 'Infectious Disease' named entity 'HCQ' named entity 'control group' named entity 'RT-PCR' named entity 'coughing' named entity 'COVID-19' named entity 'HCQ' named entity 'pharyngeal' named entity 'hydroxychloroquine' named entity 'follow-up' named entity 'HCQ' named entity 'clearance rate' named entity 'medRxiv' named entity 'discover America' named entity 'HCQ' named entity 'azithromycin' named entity '2.2' named entity 'EMA' named entity 'CT images' named entity 'HCQ' named entity 'coprimary' named entity 'control group' named entity 'chloroquine' named entity 'HCQ' named entity 'HCQ' named entity 'antiviral therapies' named entity 'pneumonia' named entity 'viral load' named entity 'medRxiv' named entity 'HCQ' named entity 'HCQ' named entity 'COVID-19' named entity 'sample size' named entity 'virus' named entity 'SNS' named entity 'June 1' named entity 'follow-up' named entity 'odds ratio' named entity 'oxygen' named entity 'follow-up' named entity 'antibody' named entity 'ARDS' named entity 'COVID-19' named entity 'contraindication' named entity 'adaptive design' named entity 'traditional Chinese medicine' named entity 'Coronavirus' named entity 'Shanghai' named entity 'plasma'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software